Abstract：
BACKGROUND: The prognosis of patients with angioimmunoblastic T cell lymphoma (AITL) remains dismal, with their 5-year overall survival (OS) and progression-free survival (PFS) rates of 32-41% and 18-38%, respectively. Spleen involvement occurs in a proportion of patients with AITL. But still, it is unclear whether spleen involvement impacts the prognosis of AITL patients. In this study, we aim to establish new prognostic indicators for the identification of high-risk patients to draft optimal treatment regimens.
METHODS: We collected and counted the clinical data of 54 patients with AITL treated with CHOP-based first-line chemotherapy regimen between 2010 and 2021 at Hubei Cancer Hospital and Hunan Cancer Hospital. In addition, all patients received PET-CT scan prior to receiving treatment. We performed univariate and multivariate analyses to assess the predictive role of tumor characteristics, laboratory, and radiographic data for the prognosis of AITL.
RESULTS: We observed that PFS and OS are worse in patients with high ECOG scores, spleen involvement, and low serum albumin levels in patients with AITL. In univariate analysis, stage (HR 3.515 [1.142-10.822], p = 0.028) and spleen involvement (HR 8.378 [1.085-64.696, p = 0.042) were correlated with PFS in patients with AITL. Besides, stage (HR 3.439 [1.108-10.674], p = 0.033) and spleen involvement (HR 11.002 [1.420-85.254], p = 0.022) were significantly correlated with OS. Consistently, spleen involvement was correlated with OS (HR 16.571 [1.350-203.446], p = 0.028) and PFS (HR 10.905 [1.037-114.690], p = 0.047) in AITL patients in a multivariate analysis.
CONCLUSIONS: This study demonstrates that spleen involvement might be used as a prognostic indicator for AITL patients.
METHODS: We collected and counted the clinical data of 54 patients with AITL treated with CHOP-based first-line chemotherapy regimen between 2010 and 2021 at Hubei Cancer Hospital and Hunan Cancer Hospital. In addition, all patients received PET-CT scan prior to receiving treatment. We performed univariate and multivariate analyses to assess the predictive role of tumor characteristics, laboratory, and radiographic data for the prognosis of AITL.
RESULTS: We observed that PFS and OS are worse in patients with high ECOG scores, spleen involvement, and low serum albumin levels in patients with AITL. In univariate analysis, stage (HR 3.515 [1.142-10.822], p = 0.028) and spleen involvement (HR 8.378 [1.085-64.696, p = 0.042) were correlated with PFS in patients with AITL. Besides, stage (HR 3.439 [1.108-10.674], p = 0.033) and spleen involvement (HR 11.002 [1.420-85.254], p = 0.022) were significantly correlated with OS. Consistently, spleen involvement was correlated with OS (HR 16.571 [1.350-203.446], p = 0.028) and PFS (HR 10.905 [1.037-114.690], p = 0.047) in AITL patients in a multivariate analysis.
CONCLUSIONS: This study demonstrates that spleen involvement might be used as a prognostic indicator for AITL patients.
摘要：
背景：血管免疫母细胞性T细胞淋巴瘤（AITL）患者的预后仍然不佳，他们的5年总生存率（OS）和无进展生存率（PFS）分别为32-41％和18-38％，分别。一定比例的AITL患者发生脾脏受累。但是，目前尚不清楚脾脏受累是否影响AITL患者的预后.在这项研究中,我们旨在建立新的预后指标,以确定高危患者,从而制定最佳治疗方案.
方法：收集2010～2021年湖北省肿瘤医院和湖南省肿瘤医院54例AITL患者的临床资料。此外,所有患者在接受治疗前都接受了PET-CT扫描.我们进行了单变量和多变量分析，以评估肿瘤特征的预测作用，实验室,和AITL预后的影像学数据。
结果：我们观察到ECOG评分高的患者PFS和OS更差，脾脏受累,AITL患者的血清白蛋白水平较低。在单变量分析中，阶段(HR3.515[1.142-10.822]，p=0.028）和脾脏受累（HR8.378[1.085-64.696，p=0.042）与AITL患者的PFS相关。此外,阶段(HR3.439[1.108-10.674]，p=0.033）和脾脏受累（HR11.002[1.420-85.254]，p=0.022）与OS显著相关。始终如一，脾脏受累与OS相关(HR16.571[1.350-203.446]，p=0.028）和PFS（HR10.905[1.037-114.690]，在多变量分析中，AITL患者的p=0.047）。
结论：本研究表明，脾脏受累可作为AITL患者的预后指标。
方法：收集2010～2021年湖北省肿瘤医院和湖南省肿瘤医院54例AITL患者的临床资料。此外,所有患者在接受治疗前都接受了PET-CT扫描.我们进行了单变量和多变量分析，以评估肿瘤特征的预测作用，实验室,和AITL预后的影像学数据。
结果：我们观察到ECOG评分高的患者PFS和OS更差，脾脏受累,AITL患者的血清白蛋白水平较低。在单变量分析中，阶段(HR3.515[1.142-10.822]，p=0.028）和脾脏受累（HR8.378[1.085-64.696，p=0.042）与AITL患者的PFS相关。此外,阶段(HR3.439[1.108-10.674]，p=0.033）和脾脏受累（HR11.002[1.420-85.254]，p=0.022）与OS显著相关。始终如一，脾脏受累与OS相关(HR16.571[1.350-203.446]，p=0.028）和PFS（HR10.905[1.037-114.690]，在多变量分析中，AITL患者的p=0.047）。
结论：本研究表明，脾脏受累可作为AITL患者的预后指标。
